EditorialEditorial

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma

You Quan Li, Ni Sann Khin and Melvin L.K. Chua
Cancer Biology & Medicine February 2018, 15 (1) 1-5; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0176

References

  1. 1.↵
    2. Epstein MA,
    3. Achong BG,
    4. Barr YM.
    Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964; 1: 702–3.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Ho HC,
    3. Ng MH,
    4. Kwan HC,
    5. Chau JC.
    Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer. 1976; 34: 655–60.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Tsao SW,
    3. Tsang CM,
    4. Lo KW.
    Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017; 372(1732)
  4. 4.↵
    2. Poh SS,
    3. Chua ML,
    4. Wee JT.
    Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. Chin J Cancer. 2016; 35: 9.
    OpenUrl
  5. 5.↵
    2. Tsang CM,
    3. Deng W,
    4. Yip YL,
    5. Zeng MS,
    6. Lo KW,
    7. Tsao SW.
    Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells. Chin J Cancer. 2014; 33: 549–55.
    OpenUrl
  6. 6.↵
    2. Sun XM,
    3. Su SF,
    4. Chen CY,
    5. Han F,
    6. Zhao C,
    7. Xiao WW, et al.
    Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014; 110: 398–403.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Zeng Y,
    3. Jan MG,
    4. Zhang Q,
    5. Zhang LG,
    6. Li HY,
    7. Wu YC, et al.
    Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer. 1982; 29: 139–41.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    2. Zong YS,
    3. Sham JS,
    4. Ng MH,
    5. Ou XT,
    6. Guo YQ,
    7. Zheng SA, et al.
    Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer. 1992; 69: 3–7.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Chien YC,
    3. Chen JY,
    4. Liu MY,
    5. Yang HI,
    6. Hsu MM,
    7. Chen CJ, et al.
    Serologic markers of Epstein–Barr virus infection and nasopharyngeal carcinoma in taiwanese men. N Engl J Med. 2001; 345: 1877–82.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Cao SM,
    3. Liu ZW,
    4. Jia WH,
    5. Huang QH,
    6. Liu Q,
    7. Guo X, et al.
    Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One. 2011; 6: e19100.
  11. 11.↵
    2. Liu Y,
    3. Huang QH,
    4. Liu WL,
    5. Liu Q,
    6. Jia WH,
    7. Chang E, et al.
    Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer. 2012; 131: 406–16.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Lo YM,
    3. Chan LY,
    4. Lo KW,
    5. Leung SF,
    6. Zhang J,
    7. Chan AT, et al.
    Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59: 1188–91.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Chan KC.
    Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer. 2014; 33: 598–603.
    OpenUrl
  14. 14.↵
    2. Lin JC,
    3. Wang WY,
    4. Chen KY,
    5. Wei YH,
    6. Liang WM,
    7. Jan JS, et al.
    Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 2461–70.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Leung SF,
    3. Tam JS,
    4. Chan ATC,
    5. Zee B,
    6. Chan LYS,
    7. Huang DP, et al.
    Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem. 2004; 50: 339–45.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Chan KCA,
    3. Hung ECW,
    4. Woo JKS,
    5. Chan PKS,
    6. Leung SF,
    7. Lai FPT, et al.
    Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer. 2013; 119: 1838–44.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    2. Ji MF,
    3. Huang QH,
    4. Yu X,
    5. Liu ZW,
    6. Li XH,
    7. Zhang LF, et al.
    Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China. Cancer. 2014; 120: 1353–60.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Chan KCA,
    3. Woo JKS,
    4. King A,
    5. Zee BCY,
    6. Lam WKJ,
    7. Chan SL, et al.
    Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017; 377: 513–22.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Ferlay J,
    3. Soerjomataram I,
    4. Ervik M,
    5. Dikshit R,
    6. Eser S,
    7. Mathers C, et al.
    GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer 2013; Available from: http://globocan.iarc.fr.
  20. 20.↵
    2. Chan ATC,
    3. Hui EP,
    4. Ngan RKC,
    5. Tung SY,
    6. Cheng ACK,
    7. Ng WT, et al.
    A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT). J Clin Oncol. 2017; 35: 6002.
    OpenUrl
  21. 21.↵
    2. Lin DC,
    3. Meng X,
    4. Hazawa M,
    5. Nagata Y,
    6. Varela AM,
    7. Xu L, et al.
    The genomic landscape of nasopharyngeal carcinoma. Nat Gen. 2014; 46: 866–71.
    OpenUrlCrossRefPubMed
  22. 22.
    2. Park SM,
    3. Wong DJ,
    4. Ooi CC,
    5. Kurtz DM,
    6. Vermesh O,
    7. Aalipour A, et al.
    Molecular profiling of single circulating tumor cells from lung cancer patients. Proc Natl Acad Sci USA. 2016; 113: E8379–86.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    2. Li YY,
    3. Chung GT,
    4. Lui VW,
    5. To KF,
    6. Ma BB,
    7. Chow C, et al.
    Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017; 8: 14121.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Dahlstrom KR,
    3. Li GJ,
    4. Hussey CS,
    5. Vo JT,
    6. Wei QY,
    7. Zhao C, et al.
    Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer. 2015; 121: 3455–64.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Higginson DS,
    3. Scher ED,
    4. Yarusi B,
    5. Chan S,
    6. Mitrani L,
    7. Thompson C, et al.
    Use of human papillomavirus 16 (HPV16) cell free DNA for assessment of response to chemoradiation in HPV-Associated oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2015; 93: S78–9.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords